A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Source:http://linkedlifedata.com/resource/pubmed/id/16899611

Clin. Cancer Res. 2006 Aug 1 12 15 4628-35

Download in:

View as

Triples

General Info

PMID
16899611